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Abstract
Although there is a strong correlation between CAG repeat length and age at onset (AO) of motor
symptoms, individual Huntington disease (HD) patients may differ dramatically in onset age and
disease manifestations despite similar CAG repeat lengths. This has led to a search for genetic
factors that influence AO. In order to identify such a genetic modifier, we analysed polymorphisms
in the PGC-1alpha gene. Recent data indicate inhibition of PGC-1alpha function by mutant Htt
supporting a link between transcriptional deregulation and mitochondrial dysfunction in HD. In >
400 HD patients, a polymorphism located within intron 2, a potential recombination hot spot,
explains a small, but statistically significant, amount of the variability in AO. Our data suggest that
PGC-1alpha has modifying effects on the pathogenic process in HD.
Findings
Huntington Disease (HD) is an autosomal-dominant dis-
order due to lesions in the striatum that cause involuntary
choreiform movements and progressive behavioral and
cognitive impairment. The underlying mutation is an
expansion of an unstable CAG repeat in the HD  gene
resulting in an expanded polyglutamine tract in hunting-
tin protein (Htt) [1]. HD shows highly variable clinical
expression, as exemplified by the wide variation of AO.
The strong inverse relationship between AO and number
of CAG repeats is well-defined. Yet, there is substantial
variation in AO that is not explained by the HD repeat [2-
6].
To date, several genetic modifiers of HD have been
described in independent studies. All of these modifiers
relate to various mechanisms implicated in HD pathology
such as excitotoxicity, dopamine toxicity, metabolic
impairment, transcription deregulation, protein misfold-
ing and oxidative stress [5,7-11]. Additionally, genom-
ewide linkage scans revealed potential loci that may
contain genes that modify AO [12-14].
Increasing evidence implicates mitochondrial dysfunc-
tion and metabolic impairment in HD pathology [for
review see [15]]. In particular, PGC-1alpha (peroxisome
proliferator-activated receptor [PPAR]-g coactivator 1a) as
a key transcriptional co-regulator is an important media-
tor in protecting neurons against oxidative damage and
seems to be involved in HD pathogenesis. PGC-1alpha
induces the transcription of cellular programs regulating
mitochondrial respiration, oxidative stress defense and
adaptive thermogenesis [16]. Recent data indicate inhibi-
tion of PGC-1alpha function by mutant Htt supporting a
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link between transcriptional deregulation and mitochon-
drial dysfunction in HD [17-19]. Altered PGC-1alpha
function may, therefore, contribute to HD pathogenesis.
A total of 15 single nucleotide polymorphisms (SNPs) in
the peroxisome proliferators-activated receptor γ coactiva-
tor 1 α (PPARGC1A) gene (rs2970865, rs2970866,
rs4383605, rs2946386, rs2970869, rs17576121,
rs2970870, rs7695542, rs2970873, rs2946385,
rs12374310, rs7665116, rs2970855, rs2970848,
rs8192678) were selected for genotyping in a German HD
cohort of more than 400 unrelated patients recruited from
the Huntington Center NRW in Bochum. Clinical assess-
ment and determination of the motor AO was performed
exclusively by experienced neurologists of the Center. The
expanded CAG repeats ranged from 40 to 66 trinucleotide
units and AO ranged from 16 to 76 years of age, with a
mean of 45 years. HD CAG repeat sizes were determined
by polymerase chain reaction using an assay counting the
perfectely repeated (CAG)n units. Informed consent was
obtained from all patients and controls. The studies were
performed in a manner that fully complies with the Code
of Ethics of the World Medical Association (Declaration of
Helsinki) and was approved by the relevant university
review board.
The polymorphisms were selected from NCBI SNP data-
base due to their potential functional relevance, e.g. poly-
morphisms in the 5'-UTR were included due to their
potential to influence gene expression, and their relative
frequency. The genotype distributions of all the chosen
polymorphisms were consistent with Hardy-Weinberg
equilibrium (HWE).
Controlling for the effect of CAG repeat length on AO
revealed an R2 value of 0.729 indicating that nearly 73%
of the variation in AO could be explained by the mutation
itself (Table 1). In addition to the number of the
expanded CAG repeats, the modifying effects of the poly-
morphisms in PGC-1alpha on the AO were examined.
Here, we saw evidence of association of the rs7665116
SNP. The R2 statistic rose modestly but significantly (from
0.729 to 0.732, p = 0.025 in the additive model, TT vs TC
vs CC, and from 0.729 to 0.733, p = 0.012, in the domi-
nant model, TT vs TC+CC) when rs7665116 genotypes
were added to the regression model (Table 1). The mean
AO in patients homozygous for the wildtype allele T is
45.08 years of age, while the mean AO for patients
homozygous for the C allele is 47.3 years of age. SNP
rs2970848 in intron 7 shows a trend towards association,
for all other polymoprhism no impact on the R2 statistic
could be observed.
Figure 1 shows the HapMap r2 values among these SNPs
in the HD cohort and reflects the previously reported
rough subdivision into 2 main haplotype blocks [20]. The
first one includes the polymorphisms in the promoter
Table 1: Variability in AO attributable to the CAG repeat length was assessed by linear regression using the logarithmically 
transformed AO as the dependent variable and SNP genotypes as independent variables.
Model R2 ΔR2 % additionally explained variance P value
HD CAG 40–66 (n = 401) 0.729 - < 0.0005
PGC-1alpha Polymorphis ms
rs2970865 promoter region - - - -
rs2970866 promoter region - - - -
rs4383605 promoter region - - - -
rs2946386 promoter region - - - -
rs2970869 promoter region - - - -
rs17576121 promoter region - - - -
rs2970870 promoter region - - - -
rs7695542 promoter region - - - -
rs2970873 intron1 - - - -
rs2946385 intron2 - - - -
rs12374310 intron2 - - - -
rs7665116 intron2
0,1,2 0.732 0.003 1.1 0.025
0,1,1 0.733 0.004 1.5 0.012
rs2970855 intron5 - - - -
rs2970848 intron7 0.731 - - 0.054
rs8192678 exon 8 - - - -
R2 illustrates the relative improvement of the regression model when the genotypes are considered in addition to the CAG repeats; ΔR2 values 
quantify these differences. (-) indicates no increase in R2.Molecular Neurodegeneration 2009, 4:10 http://www.molecularneurodegeneration.com/content/4/1/10
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region and intron 1 (rs2970865, rs2970866, rs4383605,
rs2946386, rs2970869, rs17576121, rs2970870,
rs7695542, rs2970873), whereas the second includes the
SNPs located 3' downstream of rs7665116 in intron 2.
The two haplotype blocks are separated by a region of
high recombination frequency. These results comply with
the HapMap database.
The rs7665116 T > C polymorphism is located within
intron 2, a potential recombination hot spot. Sequence
alignments of multiple species show that this SNP is
located at the beginning of a 233 bp highly conserved
sequence. Yet, the rs7665116 polymorphism itself is not
conserved to any significant extent across species. No
other SNPs are described in this conserved sequence.
In silico-analysis of rs7665116 using MatInspector [21]
revealed loss of potential binding sites for cAMP-respon-
sive element binding proteins (V$CHOP.01) in case of
the C allele as compared to the wildtype T allele. On the
other hand, in case of the C allele a new binding site is
generated for v-Myb (V$VMYB.02) and X-box binding
protein RFX1 (V$RFX1.01). Yet, it can only be speculated
that the conserved region around rs7665116 represents a
regulatory region controlling constitutive functions of
PGC-1alpha. Functional studies are needed to assess
whether PGC-1alpha is a true modifier gene and to iden-
tify the causal genetic variations contributing in the
pathogenesis of HD in this region.
While this manuscript was under review, an article by
Weydt et al. was published in this journal showing a mod-
ifying effect of PGC-1alpha haploblock 2 variations upon
AO in an Italian cohort of 447 unrelated HD patients [22].
Our independent confirmation of their findings in a Ger-
man cohort strengthens the conclusion that the PGC-
1alpha gene appears to have modifying effects on the path-
ogenic process in HD and that it may be a therapeutically
useful target for development of a treatment. Yet, it will be
necessary to delineate of the precise basis for the PGC-
1alpha modifier effect in order to effectively undertake a
search for chemical compounds that delay HD onset.
Abbreviations
PGC-1alpha: peroxisome proliferator-activated receptor
gamma co-activator
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
ETF carried out the molecular genetic studies and helped
to design the study and draft the manuscript. CS and JA
had ascertained the clinical status of the patients. SW
interpreted the data and reviewed the manuscript. LA
designed the study including statistical analysis and
drafted the manuscript.
References
1. The Huntington's Disease Collaborative Research Group: A novel
gene containing a trinucleotide repeat that is expanded and
unstable on Huntington's disease chromosomes.  Cell 1993,
72:971-983.
2. Snell RG, MacMillan JC, Cheadle JP, Fenton I, Lazarou LP, Davies P,
MacDonald ME, Gusella JF, Harper PS, Shaw DJ: Relationship
between trinucleotide repeat expansion and phenotypic var-
iation in Huntington's disease.  Nat Genet 1993, 4:393-397.
3. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam
S, Starr E, Squitieri F, Lin B, Kalchman MA, et al.: The relationship
between trinucleotide (CAG) repeat length and clinical fea-
tures of Huntington's disease.  Nat Genet 1993, 4:398-403.
4. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali
M, Folstein S, Ross C, Franz M, Abbott M, et al.: Trinucleotide
repeat length instability and age of onset in Huntington's dis-
ease.  Nat Genet 1993, 4:387-392.
5. Kehoe P, Krawczak M, Harper PS, Owen MJ, Jones AL: Age of onset
in Huntington disease: sex specific influence of apolipopro-
tein E genotype and normal CAG repeat length.  J Med Genet
1999, 36:108-111.
6. The U.S.-Venezuela Collaborative Research Project and Wexler NS:
Venezuelan kindreds reveal that genetic and environmental
factors modulate Huntington's disease age of onset.  Proc Natl
Acad Sci USA 2004, 101:3498-3503.
7. Metzger S, Bauer P, Tomiuk J, Laccone F, Didonato S, Gellera C, Soliv-
eri P, Lange HW, Weirich-Schwaiger H, Wenning GK, et al.: The
S18Y polymorphism in the UCHL1 gene is a genetic modi-
fier in Huntington's disease.  Neurogenetics 2006, 7:27-30.
8. Arning L, Saft C, Wieczorek S, Andrich J, Kraus PH, Epplen JT: NR2A
and NR2B receptor gene variations modify age at onset in
Huntington disease in a sex-specific manner.  Hum Genet 2007,
122:175-82.
Schematic representation of the PGC-1alpha gene and linkage  disequilibrium (r2) in the analysed HD cohort Figure 1
Schematic representation of the PGC-1alpha gene 
and linkage disequilibrium (r2) in the analysed HD 
cohort. Black boxes and a horizontal line represent exons 
and introns respectively. The numbers in the cells denote the 
r2 between the two SNPs corresponding to the cell. Cell 
shading indicates strength of r2 as shown by the number.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Neurodegeneration 2009, 4:10 http://www.molecularneurodegeneration.com/content/4/1/10
Page 4 of 4
(page number not for citation purposes)
9. Andresen JM, Gayan J, Cherny SS, Brocklebank D, Alkorta-Aranburu
G, Addis EA, Cardon LR, Housman DE, Wexler NS: Replication of
twelve association studies for Huntington's disease residual
age of onset in large Venezuelan kindreds.  J Med Genet 2007,
44:44-50.
10. Arning L, Monté D, Hansen W, Wieczorek S, Jagiello P, Akkad DA,
Andrich J, Kraus PH, Saft C, Epplen JT: ASK1 and MAP2K6 as
modifiers of age at onset in Huntington's disease.  J Mol Med
2008, 86:485-490.
11. Metzger S, Rong J, Nguyen HP, Cape A, Tomiuk J, Soehn AS, Propping
P, Freudenberg-Hua Y, Freudenberg J, Tong L, Li SH, Li XJ, Riess O:
Huntingtin-associated protein-1 is a modifier of the age-at-
onset of Huntington's disease.  Hum Mol Genet 2008,
17:1137-1146.
12. Li JL, Hayden MR, Almqvist EW, Brinkman RR, Durr A, Dode C, Mor-
rison PJ, Suchowersky O, Ross CA, Margolis RL, et al.: A genome
scan for modifiers of age at onset in Huntington disease: The
HD MAPS study.  Am J Hum Genet 2003, 73:682-687.
13. Li JL, Hayden MR, Warby SC, Durr A, Morrison PJ, Nance M, Ross
CA, Margolis RL, Rosenblatt A, Squitieri F, et al.: Genome-wide sig-
nificance for a modifier of age at neurological onset in Hunt-
ington's disease at 6q23-24: the HD MAPS study.  BMC Med
Genet 2006, 7:71.
14. Gayán J, Brocklebank D, Andresen JM, Alkorta-Aranburu G, US-Ven-
ezuela Collaborative Research Group, Zameel Cader M, Roberts SA,
Cherny SS, Wexler NS, Cardon LR, Housman DE: Genomewide
linkage scan reveals novel loci modifying age of onset of
Huntington's disease in the Venezuelan HD kindreds.  Genet
Epidemiol 2008, 5:445-453.
15. Gil JM, Rego AC: Mechanisms of neurodegeneration in Hunt-
ington's disease.  Eur J Neurosci 2008, 27:2803-2820.
16. Puigserver P, Spiegelman BM: Peroxisome proliferatoractivated
receptor-g coactivator 1a (PGC-1a): transcriptional coacti-
vator and metabolic regulator.  Endocr Rev 2003, 24:78-90.
17. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D:
Transcriptional repression of PGC-1alpha by mutant hunt-
ingtin leads to mitochondrial dysfunction and neurodegener-
ation.  Cell 2006, 127:59-69.
18. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jäger S, Handschin C,
Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM: Sup-
pression of reactive oxygen species and neurodegeneration
by the PGC-1 transcriptional coactivators.  Cell 2006,
127:397-408.
19. Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF,
Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD, Cui
L, Beyer RP, Easley CN, Smith AC, Krainc D, Luquet S, Sweet IR,
Schwartz MW, La Spada AR: Thermoregulatory and metabolic
defects in Huntington's disease transgenic mice implicate
PGC-1alpha in Huntington's disease neurodegeneration.  Cell
Metab 2006, 4:349-62.
20. Iglseder B, Oberkofler H, Felder TK, Klein K, Paulweber B, Krempler
F, Tregouet DA, Patsch W: Associations of PPARGC1A haplo-
types with plaque score but not with intima-media thickness
of carotid arteries in middle-aged subjects.  Stroke 2006,
37:2260-2265.
21. Werner T: Computer-assisted analysis of transcription con-
trol regions. Matinspector and other programs.  Methods Mol
Biol 2000, 132:337-349.
22. Weydt P, Soyal S, Gellera C, DiDonato S, Weidinger C, Oberkofler
H ,  L a n d w e h r m e y e r  B ,  P a t s c h  W :  The gene coding for PGC-
1alpha modifies age at onset in Huntington's Disease.  Molec-
ular Neurodegeneration 2009, 4:3.